JOGO Health

Executive Summary

JOGO Health is a digital health company pioneering a non-invasive, AI-powered platform for chronic pain management and neuromuscular rehabilitation. Its FDA-cleared system integrates wearable EMG sensors with real-time biofeedback and pain neuroscience education, leveraging neuroplasticity to improve patient outcomes. Targeting large addressable markets such as chronic pain (affecting over 50 million US adults), stroke recovery, Parkinson's disease, and incontinence, JOGO offers a scalable, drug-free alternative to opioids and invasive procedures. The platform's ability to provide personalized, at-home care positions it as a disruptive force in musculoskeletal and neurological rehabilitation, with potential to reduce healthcare costs and improve quality of life. With a strong IP portfolio and growing clinical evidence, JOGO Health is well-positioned to capture share in the rapidly expanding digital therapeutics market, projected to exceed $10 billion by 2027. The company's differentiated approach, combining neuroscience-based education with biometric feedback, addresses the root causes of chronic pain and motor dysfunction rather than merely masking symptoms. Early adoption by leading rehabilitation centers and positive patient outcomes indicate strong product-market fit. JOGO's business model, focusing on direct-to-consumer and B2B channels (including clinics and health systems), offers multiple revenue streams. While competition from other digital health players exists, JOGO's FDA clearance and focus on neuroplasticity provide a competitive moat. The company's recent funding rounds and strategic partnerships suggest accelerating commercial traction. However, challenges include scaling insurance reimbursement and demonstrating long-term efficacy in larger trials. Overall, JOGO Health represents a compelling investment opportunity in the intersection of AI, digital health, and neurology.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indications (e.g., stroke rehabilitation)70% success
• Q4 2026Strategic partnership with major health system or insurer60% success
• H2 2026Publication of pivotal clinical trial results in peer-reviewed journal80% success